Published in Managed Care Business Week, November 9th, 2004
According to published research from Sweden, "therapeutic angiogenesis is a potential treatment modality for myocardial ischemia. Plasmid human vascular endothelial growth factor A165 (phVEGF-A165 ), plasmid human platelet derived growth factor (phPDGF))-BB, or a combination of the two were injected into the myocardial infarct border zone in rats 7 days after ligation of the coronary left anterior descending artery. Cardiac function was measured by echocardiography."
"Hearts were harvested 1 and 4 weeks after plasmid injection....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.